Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Alabama now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Alabama covers just ...

Boone County battled a number of challenges and achieved unprecedented successes in 2023. And the previously sleepy, agricultural county's economy, housing and culture will never be the same as before ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

IBJ has reported extensively on numerous projects throughout this year in the core of Indianapolis and across the area—some ...

By itself, it’s not enough, but body mass index has years of evidence behind it and still has a place in clinical assessments ...

After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to ...